PFSA

Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.

Wall Street analysts forecast PFSA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFSA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Profusa Inc revenue for the last quarter amounts to -21.71M USD, increased 6742.44 % YoY.

Profusa Inc. EPS for the last quarter amounts to -10617386.00 USD, increased 3516.71 % YoY.

Profusa Inc (PFSA) has 0 emplpoyees as of January 07 2026.

Today PFSA has the market capitalization of 8.68M USD.